In line with previous data, our results show that single-agent selinexor is less effective in inducing cytotoxicity towards CLL cells carrying del(17p) and/or TP53 mutations (TP53 disrupted [TP53dis] subset). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.